<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041790</url>
  </required_header>
  <id_info>
    <org_study_id>B78_02MCI2003</org_study_id>
    <nct_id>NCT05041790</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to&#xD;
      evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with&#xD;
      degenerative mild cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomised in a 1:1 ratio to receive either Choline Alfoscerate or its&#xD;
      placebo. Investigational Products(IP, Choline Alfoscerate or its placebo) will be&#xD;
      administered 3 times a day per oral during the treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Definition of maintained/improved of cognitive function: decreased by more than or equal to 0 point of modified ADAS-Cog score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than or equal to 0 points for modified ADAS-Cog score at 24 weeks compared to baseline</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than 2 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects reduced by more than 4 points of modified ADAS-Cog score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Modified ADAS-Cog score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
    <description>The Modified ADAS-Cog 13 scale has a total of 85 points, and the higher the score, the higher the severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects increased by more than or equal to 0 point of K-MMSE-2 score at 24 and 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of K-MMSE-2 score at 24 to 48 weeks compared to baseline</measure>
    <time_frame>Baseline, 24 weeks, 48 weeks</time_frame>
    <description>K-MMSE-2 scale has a total of 30 points, and the lower the score, the higher the severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of CDR-SB score at 48 weeks compared to baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>CDR-SB calculates the CDR score as Sum of Boxes, in which case, the score in the six areas obtained by the evaluation is added as it is, and the range of the total score is 0 to 30, and the higher the score, the more severe the degree of dementia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Choline Alfoscerate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline Alfoscerate</intervention_name>
    <description>Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.</description>
    <arm_group_label>Choline Alfoscerate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 55 years&#xD;
&#xD;
          2. Diagnosis of mild cognitive impairment due to Alzheimer's disease that meets NIA-AA&#xD;
             criteria&#xD;
&#xD;
          3. Diagnosed with mild cognitive impairment on SNSB&#xD;
&#xD;
          4. Delayed recall score of SVLT ≤ &quot;average -1.5 standard deviation&quot;&#xD;
&#xD;
          5. K-MMSE-2 score ≥ 24&#xD;
&#xD;
          6. The CDR score 0.5, and the memory item score 0.5 or 1 point&#xD;
&#xD;
          7. Patients with caregivers who are in regular contact, can visit together&#xD;
&#xD;
          8. Walk or move using walking aids (i.e., walkers, walking sticks or wheelchairs)&#xD;
&#xD;
          9. Sufficient vision, hearing, language skills, motor skills, and understanding to follow&#xD;
             the examination procedure.&#xD;
&#xD;
         10. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of dementia (including secondary dementia due to Alzheimer's disease,&#xD;
             vascular dementia, infections of the central nervous system (e.g., HIV, syphilis,&#xD;
             Creutzfeld-Jacob disease), Pixie disease, Huntington's disease, Parkinson's disease,&#xD;
             etc.)&#xD;
&#xD;
          2. Medication of dementia within the past three months&#xD;
&#xD;
          3. Brain functional improvement medication in the past six weeks.&#xD;
&#xD;
          4. Medication that may affect cognitive function during clinical trials&#xD;
&#xD;
          5. No studies (no regular school entrance), illiteracy&#xD;
&#xD;
          6. Significant neurological conditions (such as stroke, multiple sclerosis, severe head&#xD;
             trauma with loss of consciousness, cerebral palsy, cerebral tumor, cerebral&#xD;
             infarction, spinal infarction or central nervous system infection) and/or evidence (CT&#xD;
             or MRI results performed within the past 12 months or during screening)&#xD;
&#xD;
          7. Abnormal results from Vitamin B12, Thyroid Stimulated Hormone Test (TSH), HIV-Ab, and&#xD;
             VDRL test contribute to or contribute to cognitive impairment of the subject&#xD;
&#xD;
          8. Serious mental disorders such as severe depression, schizophrenia, alcoholism, drug&#xD;
             dependence, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeHong Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center Institutional Review Board</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JaeHong Lee, MD</last_name>
    <phone>+82-2-3010-3446</phone>
    <email>jhlee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center Institutional Review Board</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>JaeHong Lee, MD</last_name>
      <phone>+82-2-3010-3446</phone>
      <email>jhlee@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Choline Alfoscerate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

